UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37702 Amgen Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) One Amgen Center Drive Thousand Oaks California QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES E ...

Amgen (AMGN) reported $8.15 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 9.4%. EPS of $4.90 for the same period compares to $3.96 a year ago.The reported revenue represents a surprise of +2.47% over the Zacks Consensus Estimate of $7.95 billion. With the consensus EPS estimate being $4.16, the EPS surprise was +17.79%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expect ...

Core Viewpoint - Amgen reported quarterly earnings of $4.90 per share, exceeding the Zacks Consensus Estimate of $4.16 per share, and showing an increase from $3.96 per share a year ago, representing an earnings surprise of 17.79% [1][2] Financial Performance - The company achieved revenues of $8.15 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 2.47%, and up from $7.45 billion year-over-year [2] - Over the last four quarters, Amgen has exceeded consensus EPS estimates four times and topped revenue estimates three times [2] Stock Performance - Amgen shares have increased approximately 11.6% since the beginning of the year, contrasting with a decline of -5.3% in the S&P 500 [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $5.29 on revenues of $8.82 billion, and for the current fiscal year, it is $20.57 on revenues of $34.99 billion [7] - The outlook for the Medical - Biomedical and Genetics industry is favorable, ranking in the top 32% of over 250 Zacks industries, suggesting potential for outperformance [8]

Amgen (AMGN) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Company Participants Justin Claeys - VP of IRRobert Bradway - Chairman, CEO & PresidentMurdo Gordon - Executive VP of Global Commercial OperationsJames Bradner - Executive VP of Research & Development and Chief Scientific OfficerPeter Griffith - Executive VP & CFOSalveen Richter - Biotechnolgy Equity ResearchMike Yee - Managing DirectorChris Schott - Managing DirectorUmer Raffat - Senior Managing DirectorMatt Phipps - Group Head - BiotechnologyAlex ...

Amgen (AMGN) Q1 2025 Earnings Call May 01, 2025 04:30 PM ET Speaker0 My name is Julianne, and I will be your conference facilitator today for the Amgen Q1 FY twenty twenty five Earnings Conference Call. All lines have been placed on mute to prevent any background noise. There will be a question and answer session at the conclusion of the last speaker's prepared remarks. In order to ensure that everyone has a chance to participate, we would like to request that you limit yourself to asking one question durin ...

Q1 '25 Earnings Call May 1, 2025 Safe Harbor Statement This presentation contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla® (a ...

Exhibit 99.1 News Release One Amgen Center Drive Thousand Oaks, CA 91320-1799 Telephone 805-447-1000 www.amgen.com AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS THOUSAND OAKS, Calif. (May 1, 2025) - Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2025. "Demand for our products was strong globally in the first quarter. Ongoing new product launches and successful Phase 3 trial results for several products make us feel confident in our long-term growth prospects," said Rober ...

THOUSAND OAKS, Calif., May 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2025."Demand for our products was strong globally in the first quarter. Ongoing new product launches and successful Phase 3 trial results for several products make us feel confident in our long-term growth prospects," said Robert A. Bradway, chairman and chief executive officer.Key results include: For the first quarter, total revenues increased 9% to $8.1 billion in comparison t ...

Amgen (AMGN) will report first-quarter 2025 results on May 1, after market close. In the last reported quarter, the company beat earnings expectations by 5.57%. The Zacks Consensus Estimate for first-quarter sales and earnings is pegged at $7.96 billion and $4.16 per share, respectively. (Find the latest earnings estimates and surprises on Zacks Earnings Calendar.)Factors to Consider for AmgenAmgen’s product sales are expected to have been driven by strong volume growth of products like Evenity, Repatha, Ky ...

THOUSAND OAKS, Calif., April 28, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2025 financial results on Thursday, May 1, 2025, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.Live audio of the conference cal ...